CHAPEL HILL, N.C., Oct 1, 2002 (BUSINESS WIRE) -- POZEN Inc. (Nasdaq: POZN)
announced today that John R. Plachetka, Pharm.D., the company's chairman,
president and chief executive officer, will be speaking to investors at the UBS
Warburg Global Life Sciences Conference on Tuesday, October 8, at 12:00 p.m.
Dr. Plachetka will provide an overview of POZEN's business.
The presentation will be broadcast live and archived on POZEN's investor
relations home page at www.pozen.com.
POZEN is a pharmaceutical development company committed to building a portfolio
of products with significant commercial potential in select therapeutic areas.
POZEN's initial focus is on developing products for migraine therapy, a global
market expected to exceed $2.8 billion this year. The company's common stock is
traded on The Nasdaq Stock Market under the symbol "POZN."
Chief Financial Officer
Director, Investor Relations